Natco Pharma Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026. The certificate, provided by Venture Capital and Corporate Investments Private Limited, confirms that securities received for dematerialization have been processed. This involves the mutilation and cancellation of share certificates after verification, with the depositories (NSDL and CDSL) updated as the registered owners within 15 days of receipt of valid dematerialization request forms (DRF) and share certificates. The company has also furnished these details to the stock exchanges where its securities are listed. This regulatory filing ensures compliance with depository and participant regulations, confirming the smooth processing of share dematerialization and updating of ownership records. The company secretary and compliance officer of Natco Pharma Limited, Ch. Venkat Ramesh, acknowledged the submission.
